BTIG Builds Out Equity Research Group with Biotechnology Analyst Robert C. Hazlett, III

New York – October 26, 2016 – BTIG, LLC announced today that Robert C. Hazlett, III has joined the firm’s Equity Research Group as a Managing Director. Based in BTIG’s New York office, Mr. Hazlett will cover small and mid-capitalization biotechnology companies within the Healthcare Equity Research division.

“Robert’s biotechnology coverage provides another important dimension to our Healthcare Equity Research team,” said Karen Blando, Director of Research at BTIG. “Biotechnology is a notable area of focus for our clients, and Robert’s expertise will add to our already strong healthcare offering.”

Mr. Hazlett has nearly 20 years of experience conducting biotechnology and pharmaceutical equity research. Prior to joining BTIG, he was a Biotechnology Equity Research Analyst at Ladenburg Thalmann & Co. Previously, Mr. Hazlett was a Senior Research Analyst at Roth Capital Partners. He accumulated over a decade of experience in emerging, specialty and large cap pharmaceuticals while at BMO Capital Markets, Suntrust Robinson Humphrey, Lehman Brothers and UBS. In 2015, Mr. Hazlett was recognized as a top stock picker in the biotechnology sector by the Thomson Reuters’ StarMine Analyst Awards.

“As the latest addition to our Healthcare Equity Research team, Robert will be an extraordinary resource for our clients,” said Scott Kovalik, Co-Founder and Chief Executive Officer of BTIG. “With Robert’s experience and insight, he will increase our visibility into the biotechnology sector.”

About BTIG
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 500 employees, BTIG, LLC and its affiliates operate out of 14 cities in North America, Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs, fixed income (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global sales, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more. Disclaimer:

Media Contacts:
Jill Gordon
212.279.3115, ext. 226

[email protected]

Amanda Gold

[email protected]